1. Show article details.

    J&J, Glaxo settle U.S. lawsuit over allergy ads

    Reuters – 6:07 PM ET 03/30/2015

    GlaxoSmithKline Plc (GSK) has agreed to settle a lawsuit by Johnson & Johnson (JNJ) accusing it of using false advertising at the start of the U.S. allergy season to grab market share.

  2. Show article details.

    BULLET: US CORPORATES: Further to bullet at 09:26ET --.......

    Market News Intl Fixed Income Bullets – 9:33 AM ET 03/30/2015

    US CORPORATES: Further to bullet at 09:26ET -- Janney Montgomery corporate credit analyst Jody Lurie noted that "firms are growing their businesses by putting cash to work and taking advantage of cheap debt" whereas the low-growth landscape over the past few years spurred more spin-offs as companies sought to please stockholders. She said that the "emergence of the 'mega-deals' space reflects the non-cyclicality of the industry (i.e., these companies can take risks in the current environment), but also the lack of organic growth available globally," adding that this "trend will likely continue to fuel sizable debt offerings." In addition to UnitedHealth's (UNH) purchase of Catamaran and Teva's acquisition of Auspex, at least 20 deals valued in the area of more than $1.0 billion "have been announced or rumored since the start of the year," including AbbVie's (ABBV) $19.8Bn bid for Pharmacyclics (PCYC) to top Johnson & Johnson's (JNJ) $18.0Bn bid and Pfizer's purchase of Hospira (HSP) for $16.8Bn, Lurie observed.

  3. Show article details.

    New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia

    PR Newswire – 2:31 AM ET 03/29/2015

    TITUSVILLE, N.J., March 29, 2015 Three-month paliperidone palmitate, an investigational atypical antipsychotic, significantly delayed time to relapse compared to placebo in patients with schizophrenia, according to a new Phase 3 clinical study published this week in the Journal of the American Medical Association Psychiatry.

  4. Show article details.

    Johnson & Johnson to Webcast Annual Meeting of Shareholders

    PR Newswire – 8:00 AM ET 03/27/2015

    NEW BRUNSWICK, N.J., March 27, 2015 Johnson & Johnson (JNJ) will webcast its Annual Meeting of Shareholders at 10 a.m. on Thursday, April 23, 2015, from the State Theatre in New Brunswick, N.J. Investors and other interested parties may access the live audio webcast of the meeting by visiting the Company's website at www.jnj.com and clicking on the webcast icon.

  5. Show article details.

    BRIEF-Philips enters pact with Janssen for handheld blood test

    Reuters – 4:04 AM ET 03/25/2015

    Koninklijke Philips Nv. * Philips enters into collaboration with Janssen to develop new handheld blood test to support care of patients with neuropsychiatric disorders. * Philips will be responsible for development and manufacturing of handheld test.

  6. Show article details.

    Cash piles, activists push stock buybacks to near record levels

    MarketWatch – 4:28 PM ET 03/23/2015

    EPS boost, activist investors, record cash-driving trend. SAN FRANCISCO-- The amount of money spent on stock buybacks in 2014 hit its highest level since the financial crisis, and while that may help companies meet their earnings-per-share figures, there's concern that investors are becoming addicted to the practice. S&P 500 Index companies spent $553.3 billion on share repurchases in 2014, up 16.3% from the prior year, according to Howard Silverblatt, senior index analyst at...

  7. Show article details.

    J&J's Janssen scores partial victory in second Risperdal trial

    Reuters – 6:20 PM ET 03/20/2015

    A Philadelphia jury on Friday found that Johnson & Johnson's Janssen Pharmaceuticals failed to warn that antipsychotic drug Risperdal could cause male breast growth, in a case filed by a young man who had taken the drug, but it awarded no damages after finding no direct link to the man's condition.

  8. Show article details.

    Street gushes over Alzheimer's drug, but some worry about overreaction

    MarketWatch – 1:00 PM ET 03/20/2015

    Several analysts raise target price on Biogen Idec (BIIB). LOS ANGELES-- "Yeah, it's that good." That was the simple, yet typical review of one of several Wall Street analysts who gushed Friday over Biogen Idec Inc.' s Phase 1 study results for its Alzheimer's treatment, now known under the test moniker of BIIB037.

  9. Show article details.

    New drugs still out of reach for most in India, world TB hotspot

    Reuters – 9:57 AM ET 03/20/2015

    The case of a Mumbai tailor cured of an extremely resistant form of tuberculosis this week has revived debate over a new drug to which the Indian government has limited access, prompting calls for change. Dr Zarir Udwadia, the chest physician who treated the tailor, said the government needed to do a "a lot more" to control tuberculosis in India, home to the world's largest number of TB patients.

  10. Show article details.

    FDA panel to discuss Ebola vaccine development in May

    Reuters – 8:16 AM ET 03/18/2015

    The U.S. Food and Drug Administration said an advisory panel will discuss the development of Ebola vaccines, days after an American health worker was flown back after being tested positive for Ebola in Sierra Leone. The federal health regulator would discuss the development of vaccines on May 12, it announced on its website on Wednesday.

  11. Show article details.

    Apple still buyback king as repurchases overall slow down

    MarketWatch – 4:41 PM ET 03/17/2015

    S&P 500 buyback pace sees first year-over-year quarter decline in 3 years. SAN FRANCISCO-- Apple Inc. (AAPL) easily retained its title of king of the share buybacks for the past quarter and year as the pace of repurchases slows down from a post-financial crisis high. Apple (AAPL) spent more than four times as much as any other company on share buybacks in 2014, accounting for just over 10% of the money spent on repurchases on the S&P 500. Buybacks for the S&P 500 Index increased 17.6% to $564.7...

  12. Show article details.

    Drug makers pool $100 million for dementia study

    MarketWatch – 12:08 PM ET 03/17/2015

    Five drug makers are pooling a total of $100 million in a venture capital fund along with the British government and a charity to help find treatments for Alzheimer's and other forms of dementia, reports said Tuesday. The companies pitching in are Biogen Idec Inc. (BIIB), GlaxoSmithKline, Johnson& Johnson, Eli Lilly& Co. and Pfizer Inc. The U.K. government along with Alzheimer's Research U.K. are part of the effort as well. Partners in the effort will search for and invest in the most...

  13. Show article details.

    Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

    PR Newswire – 11:26 AM ET 03/17/2015

    NEW BRUNSWICK, N.J., March 17, 2015Johnson & Johnson (JNJ) will host a conference call for investors at 8:30 a.m. on Tuesday, April 14th, to review first-quarter results. Investors and other interested parties may access the conference call in the following ways: About Johnson & Johnson Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson.

  14. Show article details.

    Johnson & Johnson Announces Strategic Investment Alliance to Combat Dementia Globally

    PR Newswire – 4:15 AM ET 03/17/2015

    NEW BRUNSWICK, N.J., March 17, 2015 Johnson & Johnson (JNJ) today announced that its Janssen Pharmaceutical Companies will invest $10 million in a new UK government-led global dementia discovery fund that will support innovative research to help find new ways to prevent and treat dementia and Alzheimer's disease.

  15. Show article details.

    Dementia drug research aided by $100 mln venture capital fund

    Reuters – 4:00 AM ET 03/17/2015

    The world's first venture capital fund dedicated to finding new ways to prevent and treat dementia has raised $100 million with the backing of the British government and several of the world's leading drugmakers. The Global Dementia Discovery Fund is unique in focusing on a single difficult to treat disorder and in bringing together industry and government.

  16. Show article details.

    Galapagos ends long-running R&D partnership with Janssen

    Reuters – 3:30 AM ET 03/17/2015

    Belgian-Dutch biotech group Galapagos said on Tuesday that it had terminated its research alliance for inflammatory diseases with Janssen Pharmaceutica which it had started in 2007.

  17. Show article details.

    Warning Prompts Shift In Surgeries on Women

    DJ Business News – 8:05 PM ET 03/16/2015

    Gynecologists in the U.S. have changed the way they perform hysterectomies now that they no longer can readily use a popular medical device that was found to spread hidden cancers in some women, according to doctors, hospitals and a new study. While some surgeons remain dismayed about new limits imposed on the tool, called a laparoscopic power morcellator, concerns that its loss would lead to major problems or a dramatic shift to open surgery don't appear to have materialized.

  18. Show article details.

    Pharmacyclics cancer drug successful as combination therapy - independent panel

    Reuters – 5:08 PM ET 03/16/2015

    An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc (PCYC) and Johnson & Johnson's Imbruvica, after the treatment was successful against two similar forms of cancer in combination with other drugs.

  19. Show article details.

    Pharmacyclics: Imbruvica Shows Benefits in Study

    DJ Business News – 4:25 PM ET 03/16/2015

    Pharmacyclics Inc. (PCYC) said an independent data monitoring committee recommended that a late-stage study of its Imbruvica drug be unblinded based on significant benefits seen in the leukemia and lymphoma patients that received the drug. Earlier this month, AbbVie Inc. (ABBV) reached a $21 billion cash-and-stock deal for Pharmacyclics (PCYC), an acquisition that would give AbbVie (ABBV) a presence in the multibillion-dollar blood-cancer market, and lessen its reliance on an aging rheumatoid-...

  20. Show article details.

    Independent panel recommends unblinding study after Imbruvica shows clear benefit

    Reuters – 3:42 PM ET 03/16/2015

    An independent panel recommended unblinding a late-stage study testing Pharmacyclics Inc (PCYC) and Johnson & Johnson's Imbruvica, after the treatment was successful in treating two types of cancer in combination with other drugs.

Page:

Today's and Upcoming Events

  • Apr
    14

    JNJ to announce Q1 earnings Before Market (Confirmed)

  • Apr
    14

    JNJ Earnings Conference Call at 8:30 AM Listen

  • Apr
    23

    Shareholders Meeting

Past Events (last 90 days)

  • Feb
    20

    JNJ ex-Dividend for $0.70 on 2/20/2015

    • Announce Date: 1/5/2015
    • Record Date: 2/24/2015
    • Pay Date: 3/10/2015
Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.